Severe Antiretroviral Therapy-Induced Toxic Epidermal Necrolysis in a Child by Norris, Joseph M. et al.
 
Case Rep Dermatol 2012;4:31–36 
DOI: 10.1159/000336569 
Published online: 
February 8, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–6567 
www.karger.com/cde 
This is an Open Access article licensed under the terms of the Creative Commons 
Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable 
to the online version of the article only. Distribution for non-commercial purposes only.   
 
                      Dr Lyn F. Dowds    David Gordon Memorial Hospital 
P.O. Box 5 
Livingstonia, Rumphi District (Malawi) 
Tel. +265 99 576 7718, E-Mail drldowds @ gmail.com 
 
31 
   
Severe Antiretroviral 
Therapy-Induced Toxic 
Epidermal Necrolysis in a Child 
Joseph M. Norris    Laura H. Stuttaford    Lyn F. Dowds  









Toxic epidermal necrolysis (TEN) is a rare and life-threatening condition characterised by 
extensive epidermal detachment and mucosal erosion. Adverse drug reaction is a strongly 
correlated causative factor and TEN is currently considered the most severe end of a 
spectrum of drug-induced mucocutaneous diseases, including Stevens-Johnson syndrome. 
Attaining an accurate and detailed patient history is critical for identifying potential 
causative agents, which can prove challenging; particularly in cultures such as that of 
Malawi. TEN lacks definitive management and the use of immunomodulation, such as with 
corticosteroids and intravenous immunoglobulin, remains controversial. We report a 
fascinating case of TEN associated with antiretroviral therapy. A 10-year-old female was 
given a combination of antiretroviral drugs (lamivudine, nevirapine and stavudine) as 
postexposure prophylaxis, having been raped. The child subsequently developed TEN and 
presented to our remote hospital in Malawi, where she was treated entirely with supportive 
therapy. This is an excellent example of difficult disease management in a limited-resource 
setting and provides reassuring evidence to clinicians of similar circumstance. To our 
knowledge, this is the first case report of antiretroviral therapy-induced TEN in a child. 
 
Introduction 
Toxic epidermal necrolysis (TEN or Lyell’s syndrome) is a very rare (0.05–2 cases 
per million per year) [1] and potentially lethal adverse reaction to drugs or infection. 
We describe a fascinating case of a 10-year-old female admitted to our remote and 
under-resourced hospital in Malawi, having developed TEN associated with 
antiretroviral therapy; notably, with the non-nucleoside reverse transcriptase inhibitor,  
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nevirapine. To our knowledge, this is the first case report of antiretroviral therapy-
induced TEN in a child. 
Case Report 
A 10-year-old female attended a clinic in rural Malawi, seven days after having been raped by a 
21-year-old male. The HIV-status of her attacker was unknown and so given Malawi’s HIV epidemic 
(10–12.1% for adults aged 15–49 in 2009) [2] she was prescribed a fixed-dose combination of 
antiretroviral drugs, including lamivudine 150 mg, nevirapine 200 mg and stavudine 30 mg, as 
postexposure prophylaxis. Ten days later, she presented systemically unwell with a three day history 
of fever, stomatitis and widespread pruritic rash. Her condition rapidly deteriorated and so she was 
transferred to our hospital. 
Examination revealed truncal epidermal loss and raw, oozing dermis (fig. 1a). Remaining 
epidermis featured irregular erythematous zones and flaccid bullae (fig. 1b). Nikolsky’s sign 
(tangential pressure cleaves full-thickness epidermis) and Asboe-Hansen sign (pressure extends 
blister laterally) were both positive, being indicative, but not pathognomonic, of TEN. Admission 
observations showed: heart rate was regular (122 beats/min), blood pressure was 102/70 mm Hg, 
axillary temperature was 38.7°C, respiratory rate was 34 breaths/min and peripheral O2 saturation 
was 98%. Available laboratory analyses revealed: haemoglobin was 12.6 g/dl and that she had a 
nonreactive HIV-status. Clinical diagnosis of TEN was made through confirmation of antiretroviral 
therapy prescription and with >60% body surface area epidermal detachment, by modified Lund and 
Browder chart. Absent histopathology services made tissue diagnosis impossible, but punch biopsy 
showing full-thickness epidermal necrosis was to be expected. 
Management was directed by poor-resource availability at our hospital. All previous medication 
was terminated and intravenous Ringer’s lactate 1 l and pethidine 25 mg were administered in an 
isolation room. A simple burn recovery bed-cradle was arranged to minimise epithelial and dermal 
contact with insulating blankets. Meticulous fluid-balance failed as urinary catheter insertion 
removed excessive urethral meatal epidermis. Supportive therapy was continued for 21 days, with 
graduated change to oral fluid, ibuprofen 200 mg and paracetamol 500 mg. Local food was 
supplemented to address protein-deficiency and silver sulfadiazine was regularly applied to skin for 
infection prophylaxis (fig. 1c). Ophthalmic opinion was sought and a combination eyedrop of 
tobramycin 0.3%, dexamethasone 0.1% and benzalkonium chloride 0.01% was prescribed. Painful 
erosions of conjunctival, oral and genital mucosa appeared within 24 h of admission (fig. 2a), whilst 
re-epithelialisation began after ten days. Protein-deficiency oedema and anaemia (haemoglobin was 
6.5 g/dl) occurred and resolved during the latter stages of healing (fig. 2f). Full recovery took 28 days, 
with some cutaneous scarring and abnormal pigmentation as final sequelae (fig. 1e). 
Discussion 
In 1956, Lyell described TEN as an ‘eruption resembling skin scalding’ and suggested 
potential pathomechanism: epidermal necrosis/lysis secondary to toxaemia [3]. Today, 
TEN is perceived as the most severe end of a spectrum of systemic drug-induced 
mucocutaneous conditions, including Stevens-Johnson syndrome (table 1). 
Immmunopathogenesis involves widespread keratinocyte apoptosis following 
interaction between the death receptor Fas and Fas ligand (CD95), in addition to the 
activation of the perforin/granzyme pathway [4]. 
TEN has very poor prognosis (mortality 30–50%) attributed to multiorgan failure 
and sepsis. A recent study described lower mortality in children [5] but significant 
morbidity makes dermatological, ophthalmic and paediatric consultation highly 
advisable. We recommend the severity stratification ‘SCORTEN’ scale, for accurate 
prognostic indication in sufficiently-resourced centres [6]. One negative aspect of this  
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scale, however, is the underemphasis of the extent of epidermal detachment. Patients 
with 100% body surface area involvement have far worse prognoses than those with 
only 30% involvement – though both groups of patients rank equally, in terms of 
SCRORTEN points. 
Attaining detailed patient history and terminating offending agents is essential. We 
experienced difficulties in this area as initial information was scarce, so TEN associated 
with traditional African medicine was briefly considered. Lim and Thirumoorthy 
recently reported a case of traditional Chinese medicine-induced TEN [7] and so whilst 
there are no currently recorded cases associated with African medicine, we suggest that 
this is a ripe area for research. 
Over 100 drugs have been associated with TEN. Risk of toxiderma is very high with 
antiretroviral drugs, especially in HIV-positive patients, who are 1,000 times more 
likely to develop TEN than noninfected patients [8]. In our case, the culprit was almost 
certainly the fixed combination of antiretroviral drugs (lamivudine, nevirapine and 
stavudine). Lamivudine and stavudine are relatively safe, with mild adverse cutaneous 
reactions being rarely reported. In contrast nevirapine is notorious, causing TEN in 
approximately 0.3% of patients [9] and is thus the likely single precipitant in our 
patient. All six cases of nevirapine-induced TEN in the existing literature are adults, 
who were treated in large university hospitals (table 2). Prior to our case, no report 
describes nevirapine or antiretroviral therapy-induced TEN in a child. 
Association between antiretroviral therapy/nevirapine and TEN is reinforced here, 
thus we implore prescribers to exercise pharmacovigilance. Prescription of any form of 
postexposure prophylaxis was inappropriate for our patient, as she fell outside of the 
designated 72 h prophylactic window, by 96 h. Additionally, the drugs given were 
merely standard Malawian antiretroviral drugs (unsuitable for postexposure 
prophylaxis). Lastly, the dose prescribed was neither the paediatric nor the loading 
dose – adding to the collection of serious errors. 
Once the culprit drug is removed, the patient should be rigorously supported and 
our success here illustrates this as excellent stand-alone therapy. Fluid and analgesia 
are mandatory, whilst antimicrobials are beneficial, as evidenced by absent cutaneous 
infection in our patient. Immunomodulators such as cyclosporine, N-acetylcysteine, and 
corticosteroids have been trialled with varying success, but are clearly unaffordable in 
rural, tropical healthcare settings. Reports of hastened recovery periods in patients 
given IVIG exist [10–12], but again this is limited by resource availability. Clinicians 
must utilise what is available to them and so in other limited-resource settings, 
inventive treatments for TEN such as autoclaved banana leaf dressings, have been 
employed [15]. Currently, there are no evidence-based standard guidelines for the 
treatment of TEN and the literature consists of small uncontrolled series and few case 
reports, of which ours adds to. These anecdotal reports highlight the need for a large, 
randomised control trial to ascertain definitive, first-line management. 
To the best of our knowledge, this is the first reported case of antiretroviral therapy-
induced TEN in a child. This report demonstrates how under-resourced rural African 
hospitals are, whilst still being able to provide the intense supportive care required for 
TEN management. Clinicians faced with comparable scenarios should be reassured,  
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whilst those in the developed world should pause to consider the challenges of tropical 
dermatology. 
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Table 1. Spectrum of severe cutaneous adverse drug reactions [4] 
                      EMM  SJS  SJS/TEN overlap  TEN 
                    BSA epidermal detachment  1–2%  <10%  10–30%  >30% 
                    Typical target lesions  Present  Absent  Absent  Absent 
                    Atypical target lesions  Present – raised  Present – flat  Present – flat  Present – flat 
                    Confluent purpuric macules  Absent  Present  Present  Occasionally present 
        Important differential diagnoses  Staphyloccocal scalded skin syndrome; autoimmune blistering diseases 
        BSA = Body surface area; EMM = erythema multiforme majus; SJS = Stevens-Johnson syndrome. 
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Table 2. Existing case reports of nevirapine-induced TEN 













                        Phan et al. 
(1999) [10] 
31 (male)  50  Supportive, IVIG, fluconazole, acyclovir, cephazolin  14  (Complete 
resolve) 
                        Cattelan et al. 
(2001) [11] 
26 (female)  45–50  Supportive, IVIG, prednisone  72  (Complete 
resolve) 
    22 (female)  30–35  Supportive  35  (Complete 
resolve) 
                        Claes et al. 
(2004) [12] 
39 (male)  80–90  Supportive, chlorhexidine, fluconazole, clindamycin, 
acyclovir, paracetamol, IVIG, N-acetylcysteine 
35  Toxic hepatitis 
                        Leng et al. 
(2008) [13] 
32 (male)  100  Supportive  30  (Death) 
                        Sachdev et al. 
(2011) [14] 
34 (male)  Not  
stated 
Ophthalmic: cephazolin-sodium, tobramycin-sulfate, 
propamedine-isothionate, chlorhexidine-gluconate, 
carboxymethylcellulose, homatropine-hydrobromide, 
amniotic membrane transplantation 





                        Summary  30.7 (male)  63  Various  37.2  Various 
                        ED = Epidermal detachment; IVIG = intravenous immunoglobulin. 





Fig. 1. a Truncal epidermal necrolysis and b flaccid bullae on right upper limb, on admission. c Silver 
sulfadiazine application, day 7. d Extensive lesioning, day 14. e Re-epithelialisation with altered 
pigmentation, day 21. Incidental umbilical hernia was untreated. 
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Fig. 2. Facial chronology. a Nikolsky’s sign under right eye and haemorrhagic oral erosions, on 
admission. b Eyelids oedema and lip necrosis, day 5. c Epidermal stripping and ulcerated 
conjunctivae, day 9. d Silver sulfadiazine application, day 13. e Re-epithelialisation, day 17. 
f Predominantly healed, with mild facial oedema, day 21. 
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